anti-Nipah_013
anti-Nipah_ID | anti-Nipah_013 |
anti-Nipah Drug | 3,4-Difluoro-N-[4-(1H-tetrazol-1-yl)phenyl]benzenesulfonamide |
Nipah virus strain | NiV (Malaysia-1999) |
Approaches used to test anti-Nipah activity | Experimental |
Methods used to test anti-Nipah activity | in-vitro |
Models used to test anti-Nipah activity | Vero |
Mode of infection to test anti-Nipah activity | Adsorption |
Viral titer to test anti-Nipah activity | 0.02 MOI |
Mode of Drug delivery for anti-Nipah activity | Culture |
Time of Drug delivery for anti-Nipah activity | NA |
Duration of Drug delivery for anti-Nipah activity | 72 hours |
Drug concentration used to test anti-Nipah activity | 39 μM |
Assays used to test anti-Nipah activity | TCID50 |
anti-Nipah activity | Decrease [TCID50 (<1O TCID50/ml)] |
References | Tigabu B, Rasmussen L, White EL, Tower N, Saeed M, Bukreyev A, Rockx B, LeDuc JW, Noah JW A BSL-4 high-throughput screen identifies sulfonamide inhibitors of Nipah virus. Assay Drug Dev Technol. 2014 Apr;12(3):155-61. doi: 10.1089/adt.2013.567 |
Comments | A total of 23 compounds were identified with EC50 values ranging from 3.9 to 20.0__M and selectivities >10 against NiV. Three sulfonamide compounds with EC50 values <12__M were further characterized for their point of intervention in the viral replication cycle and for broad antiviral efficacy. |